ELDN

----
DC

David-Alexandre C. Gros

CEO & Non Independent Director

Dr. David-Alexandre C. Gros, also known as DA, M.D., Ph.D., serves as Chief Executive Officer and Non-Independent Director at Eledon Pharmaceuticals, Inc. since September 09, 2020. Dr. Gros served as an advisor to Eledon since May 2020. He served as Executive Officer of Neurocrine Biosciences, Inc. since October 19, 2017, until December 31, 2017. Dr. Gros served as the President and Chief Operating Officer of Neurocrine Biosciences, Inc. from January 9, 2017 to October 19, 2017 and as its Interim Chief Financial Officer from February 15, 2017 to October 19, 2017. He co-founded Eliem Therapeutics, Inc. and served as its Director. Dr. Gros served as Chief Business Officer and Senior Vice President of Alnylam Pharmaceuticals, Inc. from June 8, 2015 to January 6, 2016 and its Principal Financial Officer from July 1, 2016 to January 6, 2016. Dr. Gros served as the Chief Strategy Officer and Executive Vice President at Sanofi since September 1, 2011. Dr. Gros covers all Group business development and acquisition activities as well as strategic planning, economic evaluation of projects, strategic intelligence and alliance management. He was an Advisor to pharmaceutical, biotechnology and diagnostic companies as a Principal and founding Member of the Healthcare Investment Banking division at Centerview Partners, in San Francisco, California. He served as a Vice President of Sanofi. Dr. Gros worked in clinical and health outcomes research at the Department of Urology of the Johns Hopkins Hospital from 1996 to 1999 and then as a Resident Physician at the University of Pennsylvania Health System from 1999 to 2000. In 2002, he joined McKinsey & Company's Pharmaceuticals & Medical Products practice as an Associate, was promoted to Engagement Manager in 2004 and to Associate Principal in 2006. In late 2006, he joined Merrill Lynch as a Vice President in Healthcare Investment Banking focusing on strategy, mergers & acquisitions and corporate finance until joining Centerview Partners in mid-2009. He served as Chief Executive Officer at Imbria Pharmaceuticals, Inc. Dr. Gros holds a B.A. from Dartmouth College in 1995, an M.D. from the Johns Hopkins University School of Medicine in 1999 and an M.B.A. from Harvard Business School in 2002.

公司职务

  • 公司名称Eledon Pharmaceuticals, Inc.
    股票代码ELDN
    职务CEO & Non Independent Director
    关联证券
    共事同僚